⏳
Showing Q3 2025 data
TAKEDA PHARMACEUTICAL CO LTD's Q4 2025 filing not yet available. Expected by Feb 14, 2026.
TAKEDA PHARMACEUTICAL CO LTD
•CIK: 1395064•Filing: Q3 2025
**TAKEDA PHARMACEUTICAL CO LTD** manages a substantial $16.4B AUM across a concentrated portfolio of 8 positions. The fund exhibits significant conviction in its top holdings, led by a dominant allocation to OVID at $9,791.6M. Further substantial exposure is maintained in EQ ($2,609.7M) and XLO ($1,243.1M), indicating a focused, high-conviction investment mandate. This structure suggests a deep, sector-specific research approach underpinning its capital deployment.
Total AUM
$16.4B
QoQ Performance
-16.3%
Positions
8
Top 10 Concentration
100.0%
Latest Filing
Q3 2025
Top Holdings Allocation
OVID
EQ
Xili
STTK
Lyel
OVID59.8%
EQ15.9%
Xilio7.6%
STTK7.5%
Lyell5.4%
AMWL2.9%
RANI0.6%
FLB0.1%
📈 Biggest Buys
—
Lyell Immunopharma, Inc.
+33.3%
5.4% of portfolio
📉 Biggest Sells
No reductions this quarter
Sector Breakdown
Other100.0%
🚪 Exited Positionssold since Q2 2025
—
HilleVax, Inc.
SOLD
$13.4B
—
Turnstone Biologics
SOLD
$321.6M
—
Third Harmonic Bio, Inc.
SOLD
$200.0M
Changes from Q2 2025
↑1 increased
Historical Filings
Q3 2025Q2 2025Q1 2025Q4 2024